https://doi.org/10.55788/dd969758
Patients with UC not only need to undergo colonoscopies for diagnostic indications, but for cancer screening as well. However, these procedures can also provoke disease flares. A prospective, randomised trial investigated if the use of carbon dioxide (CO2) for intra-procedural insufflation may bear an advantage over the regularly used air insufflation in remissive UC patients (Partial Mayo Score [PMS] ≤2). The study enrolled 91 adults with a median age of 49 years; 66% were men. Overall, the baseline characteristics were evenly distributed among the 2 study groups, e.g. for disease location, Mayo Endoscopic Subscore (MES), clinical activity, and medication.
Immediately following colonoscopy, the abdominal pain score for patients in the CO2 group was significantly lower compared with the air group, as was the score for abdominal fullness (P=0.0003 for both comparisons). At 30 minutes following procedure termination, these 2 measures were still significantly lower in patients in the CO2 group (P<0.001 for both comparisons).
The assessment of clinical recurrence (PMS ≥3) was performed at week 1 and week 8 after the colonoscopy. At week 1, no significant disparity was observed between the groups receiving air or CO2 for insufflation, both in patients with complete remission (MES0 or PMS0) nor those in partial remission (MES 1–3 or PMS 1/2). However, at week 8, the group of UC patients with partial remission who had been insufflated with CO2 instead of air had a significantly lower proportion of clinical recurrence: CO2 0% versus air 24% (P=0.048) for MES 1–3 and 0% versus 30% (P=0.022) for PMS 1/2.
The authors summarised that CO2 insufflation can reduce abdominal discomfort after colonoscopy and decrease clinical recurrence in those UC patients who do not have complete remission.
- Otake Y, et al. Efficacy of carbon dioxide insufflation during colonoscopy for patients with ulcerative colitis in clinical remission- a randomised trial. Poster EP1277, Digestive Disease Week 2022, 21–24 May, San Diego, CA, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Which women benefit most from digital breast tomosynthesis? Next Article
Positive outcomes for etrasimod in UC »
« Which women benefit most from digital breast tomosynthesis? Next Article
Positive outcomes for etrasimod in UC »
Table of Contents: DDW 2022
Featured articles
Too much hygiene: CD in later life?
IBD
Antibiotic use elevates IBD risks in senior citizens
Too much hygiene: CD in later life?
Biologic treatment decreases dementia risk in senior IBD patients
CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings
IL-23 inhibition beneficial in maintenance treatment of UC
Positive outcomes for etrasimod in UC
Colonoscopy in UC: less pain and reduced recurrence with CO2 insufflation
Upper GI
Substantial increase of oesophageal cancer prevalence in the middle-aged
Cannabis users need more sedation medication for gastroscopy
Preterm delivery and NICU admission are associated with the development of eosinophilic oesophagitis
Dupilumab promising as treatment for eosinophilic oesophagitis
Other Highlighted Research
AI-assisted colonoscopy improves adenoma detection
Faecal microbiota transplantation: a safe procedure to treat recurrent Clostridium difficile infections
Oral microbes effective for prevention of recurrent Clostridium difficile infections
Octreotide therapy beats standard of care in GIADs
Improvement in hepatic steatosis but worse lipid profile after alcohol cessation
Normal BMI in NAFLD patients is associated with a higher risk of cardiovascular disease
COVID-19 increases the mortality rates of patients with ALD
Related Articles
July 9, 2021
Atorvastatin does not reduce mortality in COVID-19
November 8, 2021
Comparison of headaches after SARS-CoV-2 vaccination
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com